Product Information
XIGDUO XR 10 MG-1,000 MG TAB is a brand product labeled by AstraZeneca Pharmaceuticals LP, priced at $19.2044 per EA under NDC 00310628030. Its NADAC has been published 598 times since Apr 22, 2015.
FDA first approved this application on Oct 29, 2014. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
10; 1000 mg/1; mg/1
Manufacturer
AstraZeneca Pharmaceuticals LPNDC
00310628030
Classification
Brand
Dosage Form
TABLET, FILM COATED, EXTENDED RELEASE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
DAPAGLIFLOZIN PROPANEDIOL; METFORMIN HYDROCHLORIDEApproval Type
New Drug (NDA)
FDA Application
NDA205649FDA Approved
10/29/2014
TE Code
AB
On Market Since
10/29/2014
Pharmacological Classes
Price Statistics
The NADAC for XIGDUO XR 10 MG-1,000 MG TAB has been published 598 times since Apr 22, 2015, and over the history we have for it it has risen 73.7%. The table below summarizes its recorded NADAC range and movement.
| Current price | $19.2044 per EA |
|---|---|
| All-time high | $19.2044 (Sep 30, 2026) |
| All-time low | $11.0530 (Apr 22, 2015) |
| 52-week high | $19.2044 |
| 52-week low | $19.1753 |
| Median price | $16.7854 |
| Average price | $16.2313 |
| Largest weekly change | +9.9% (Jan 18, 2017) |
| Weeks tracked | 598 |
| Tracking since | Apr 22, 2015 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 96% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
AstraZeneca Pharmaceuticals LP manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
dapagliflozin and metformin hydrochloride market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Biguanide class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of XIGDUO XR 10 MG-1,000 MG TAB?
The current National Average Drug Acquisition Cost (NADAC) for XIGDUO XR 10 MG-1,000 MG TAB, manufactured by AstraZeneca Pharmaceuticals LP, is $19.2044 per EA (NDC 00310628030), effective Sep 30, 2026.
How has the price of XIGDUO XR 10 MG-1,000 MG TAB changed over time?
Over the history we have for it, the NADAC for XIGDUO XR 10 MG-1,000 MG TAB has risen 73.7%. It has been tracked across 598 weekly CMS publications since Apr 22, 2015.
What are the highest and lowest recorded NADAC prices for XIGDUO XR 10 MG-1,000 MG TAB?
Since Apr 22, 2015, the NADAC for XIGDUO XR 10 MG-1,000 MG TAB has ranged from a low of $11.0530 (Apr 22, 2015) to a high of $19.2044 (Sep 30, 2026), with a median of $16.7854 per EA.
Are there cheaper alternatives to XIGDUO XR 10 MG-1,000 MG TAB?
Yes. 1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, DAPAGLIFLOZIN-METFORMIN ER 10-1,000 MG TABLET, is $0.7195 per EA — about 96% below XIGDUO XR 10 MG-1,000 MG TAB.
Who manufactures XIGDUO XR 10 MG-1,000 MG TAB?
XIGDUO XR 10 MG-1,000 MG TAB (NDC 00310628030) is labeled by AstraZeneca Pharmaceuticals LP, and CMS classifies it as a brand product.